As part of the collaboration, the companies will assess the potential of Subtle Medical ’s investigational AI algorithm, named SubtleGAD, to improve image qualities in contrast-enhanced magnetic resonance imaging (MRI) exams.
The AI-powered software leverages deep learning technology to achieve a 90% dose reduction of Gadolinium-based contrast agents (GBCAs) for contrast-enhanced MRI exams. The software helps to deliver improved image quality and support lesion detectability.
Bayer radiology research and development head Dr Olaf Weber said: “At Bayer , we are constantly striving to advance medical knowledge and provide the best possible therapeutic and diagnostic options for physicians and patients.
“We are pleased to collaborate with Subtle Medical to harness the power of AI, with the ultimate goal of providing physicians with the means for optimal diagnosis for their patients.”
MRI scans provide detailed images of patients’ bodies and help physicians monitor diseases. The use of AI in the process is expected to help radiologists accelerate imaging exam times and ensure quick and accurate diagnoses.
Subtle Medical stated that its software solutions increase the image capturing efficiency by improving the quality of low dose imaging. It also noted that the solutions are compatible with all scanner models, brands and field strengths.
Subtle Medical chief product officer Dr Ajit Shankaranarayanan said: “We are proud to collaborate with Bayer to combine our expertise and drive innovative solutions in light of the ever-increasing demands of medical imaging.
“At Subtle Medical , we are committed to continued innovation and the development of AI tools that create a meaningful impact for both radiologists and patients.”